said it has replaced W. James O'Shea, its president and chief operating officer, with Adrian Adams, the former CEO of
Adams is expected to be named Sepracor's CEO in six months. At that time, Timothy Barberich, now CEO and chairman, will remain as the chairman of the Marlborough, Mass.-based company. Sepracor makes the insomnia drug Lunesta and asthma drug Xopenex.
The announcement came after the market closed Thursday. O'Shea, 57, had been president and chief operating officer since October 1999.
Adams was CEO and president of Kos until December, when his company was acquired by
Sepracor also said former Kos executive Andrew Koven has been named to the new job of executive vice president, general counsel and secretary. He held the same post at Kos for four years. Douglas Reedich, senior vice president for legal affairs at Sepracor, will leave after providing "an orderly transition," Sepracor said.